Brainsway’s April 2026 quarterly filing reveals expanded U.S. payer reimbursement, including nurse practitioner-administered TMS therapy, driving broader clinical adoption and revenue momentum. The company also completed a $6 million milestone-based investment in neuromodulation startup Neurolief following FDA approval of its Proliv™Rx system, reinforcing a strategy of innovation pipeline expansion. With multiple FDA-cleared indications for its proprietary Deep TMS platform and accelerating marketing efforts, Brainsway is leveraging regulatory advances and partnerships to scale its treatment of mental health disorders in a predominantly U.S.-centered revenue base. Financially, the strong top-line growth and improved profitability reflect growing system sales and leases supported by an entrenched installed base and payer coverage.